Boundless Bio, Inc.

NasdaqGS:BOLD

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💊 Pharmaceuticals

Location

United States

Market Cap

USD 23.28 M

Share Price

USD 1.04

Avg Daily Volume

74,090

Change (1 day)

0.00%

Change (1 year)

Change (YTD)

-53.15%

Boundless Bio, Inc. Share Price Year-To-Date (YTD) return on June 20, 2025: -53.15%

Boundless Bio, Inc. Share Price Year-To-Date (YTD) return is -53.15% on June 20, 2025. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance. Year-to-Date (YTD) return is is the percentage change in the price of a stock from the start of the calendar year up to the current date, it shows how much the stock has gained or lost since the beginning of the year.

Boundless Bio, Inc. 52-week low Share Price is USD 2.11 on June 20, 2025, which is 102.88% above the current Share Price.
Boundless Bio, Inc. 52-week low Share Price is USD 1.04 on June 20, 2025, which is 0.00% below the current Share Price.
Boundless Bio, Inc. average Share Price for the last 52 weeks is USD 1.49.

Daily

From:

To:

Zoom:

Key data

Date	Share Price Year-To-Date (YTD) return	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)	Price to Sales Ratio (P/S)

NasdaqGS: BOLD

Boundless Bio, Inc.

CEO	Mr. Zachary Hornby
IPO Date	July 20, 2016
Location	United States
Headquarters	9880 Campus Point Drive
Employees	64
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 💊 Pharmaceuticals

Description

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.